Bioorganic & Medicinal Chemistry Letters 2005-07-01

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Erös, György Mészáros, Ferenc Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, György Kéri, László Orfi

文献索引：Bioorg. Med. Chem. Lett. 15 , 3241-6, (2005)

全文：HTML全文

摘要

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.